Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
4.370
0.00 (0.00%)
At close: Apr 8, 2026, 4:00 PM EDT
4.313
-0.057 (-1.30%)
After-hours: Apr 8, 2026, 8:00 PM EDT
Perspective Therapeutics Employees
As of December 31, 2025, Perspective Therapeutics had 166 total employees, including 163 full-time and 3 part-time employees. The number of employees increased by 26 or 18.57% compared to the previous year.
Employees
166
Change (1Y)
26
Growth (1Y)
18.57%
Revenue / Employee
$5,325
Profits / Employee
-$621,211
Market Cap
497.89M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 166 | 26 | 18.57% | 163 | 3 |
| Dec 31, 2024 | 140 | 21 | 17.65% | 138 | 2 |
| Dec 31, 2023 | 119 | 53 | 80.30% | 116 | 3 |
| Jun 30, 2022 | 66 | 5 | 8.20% | 66 | 0 |
| Jun 30, 2021 | 61 | 8 | 15.09% | 61 | 0 |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Varex Imaging | 2,400 |
| Avanos Medical | 2,287 |
| Orthofix Medical | 1,605 |
| Tactile Systems Technology | 1,086 |
| Cytek Biosciences | 702 |
| OrthoPediatrics | 602 |
| Pacific Biosciences of California | 485 |
| Beta Bionics | 423 |
CATX News
- 6 days ago - Perspective Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026 - GlobeNewsWire
- 23 days ago - Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results - GlobeNewsWire
- 7 weeks ago - Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 3 months ago - Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire
- 3 months ago - Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Perspective Therapeutics to Participate in Upcoming December Conferences - GlobeNewsWire